Related Experiment Video
Updated: Mar 18, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
New drugs in prostate cancer
Sangjun Yoo1, Se Young Choi1, Dalsan You1
1Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Abstract:
The standard primary treatment for advanced prostate cancer has been hormonal therapy since the 1940s. However, prostate cancer inevitably progresses to castration-resistant prostate cancer (CRPC) after a median duration of 18 months of androgen deprivation therapy. In patients with CRPC, docetaxel has been regarded as the standard treatment. However, survival advantages of docetaxel over other treatments are slim, and the need for new agents persists. In recent years, novel agents, including abiraterone, enzalutamide, cabazitaxel, radium-223, and sipuleucel-T, have been approved for the treatment of CRPC, and more such agents based on diverse mechanisms are under investigation or evaluation. In this article, the authors reviewed the current literature on recent advances in medical treatment of prostate cancer, especially CRPC. In addition, the authors elaborated on novel drugs for prostate cancer currently undergoing investigation and their mechanisms.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Drugs that Stabilize Microtubules
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
FDA Approved Drugs: Changes to Approved Drugs
Prodrugs
Prodrugs help overcome...
Treatment Resistant Cancers

